Z He1, C Lu, M K A Basra, A Ou, Y Yan, L Li. 1. Departments of Clinical Epidemiology and Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Abstract
BACKGROUND: The Dermatology Life Quality Index (DLQI) is one of the most frequently used scales to evaluate the impact of skin disease on patients' quality of life (QoL). There has not been psychometric evaluation of the Chinese version of DLQI in Chinese patients with psoriasis. OBJECTIVE: The objective of this study was to evaluate the psychometric properties of the Chinese version of DLQI. METHODS: Patients with psoriasis (≥ 18 years old) visiting nine hospitals in various regions of China were enrolled in the study. The DLQI, Psoriasis Disability Index (PDI) and Health Survey Short Form (SF-36) were completed. Severity of psoriasis was assessed by the Psoriasis Area Severity Index (PASI). Reliability was estimated by internal consistency. Validity was assessed using known-groups comparison, convergent validity and construct validity. RESULTS: In all, 851 patients were included in the study. The internal consistency reliability of the DLQI was high (Cronbach's alpha = 0.91). Known-groups comparison showed that the DLQI discriminated well among patients who differed in age, geographical region, duration of psoriasis and the PASI score. Evidence of convergent validity of the DLQI was proved by high correlations with the PDI and four subscales of SF-36 (role-physical, bodily pain, social functioning and role-emotional): r = 0.52-0.78. Construct validity was proved by the presence of one-factor structure that accounted for 55.9% of the variance and fitted well into the unidimensional model. CONCLUSION: The Chinese version of DLQI is a reliable and valid measure to assess patient-reported impact of skin disease and could be used in QoL and health outcome studies on Chinese psoriasis patients.
BACKGROUND: The Dermatology Life Quality Index (DLQI) is one of the most frequently used scales to evaluate the impact of skin disease on patients' quality of life (QoL). There has not been psychometric evaluation of the Chinese version of DLQI in Chinese patients with psoriasis. OBJECTIVE: The objective of this study was to evaluate the psychometric properties of the Chinese version of DLQI. METHODS:Patients with psoriasis (≥ 18 years old) visiting nine hospitals in various regions of China were enrolled in the study. The DLQI, Psoriasis Disability Index (PDI) and Health Survey Short Form (SF-36) were completed. Severity of psoriasis was assessed by the Psoriasis Area Severity Index (PASI). Reliability was estimated by internal consistency. Validity was assessed using known-groups comparison, convergent validity and construct validity. RESULTS: In all, 851 patients were included in the study. The internal consistency reliability of the DLQI was high (Cronbach's alpha = 0.91). Known-groups comparison showed that the DLQI discriminated well among patients who differed in age, geographical region, duration of psoriasis and the PASI score. Evidence of convergent validity of the DLQI was proved by high correlations with the PDI and four subscales of SF-36 (role-physical, bodily pain, social functioning and role-emotional): r = 0.52-0.78. Construct validity was proved by the presence of one-factor structure that accounted for 55.9% of the variance and fitted well into the unidimensional model. CONCLUSION: The Chinese version of DLQI is a reliable and valid measure to assess patient-reported impact of skin disease and could be used in QoL and health outcome studies on Chinese psoriasispatients.
Authors: Zehui He; Chuanjian Lu; Mary-Margaret Chren; Zhongzhao Zhang; Yan Li; Xiaojia Ni; Henry A Buchtel V; Paul F Ryan; Guo-Zheng Li Journal: Health Qual Life Outcomes Date: 2014-12-24 Impact factor: 3.186
Authors: Juan Wang; Yu-You Zhu; Zhong-Ying Wang; Xiu-Hua Yao; Lan-Fang Zhang; Hong Lv; Si-Ping Zhang; Bai Hu Journal: Medicine (Baltimore) Date: 2017-12 Impact factor: 1.817